Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Persistent or Recurrent Endometrial Carcinoma
NCT04251416Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in endometrial carcinoma, sponsored by Yale University. Primary endpoint: Objective Response Rate at 4 years. Started Mar 2020; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT04251416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251416.